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Influence of psychological coping on survival and
recurrence in people with cancer: systematic review
Mark Petticrew, Ruth Bell, Duncan Hunter
Abstract
Objective To summarise the evidence on the effect of
psychological coping styles (including fighting spirit,
helplessness/hopelessness, denial, and avoidance) on
survival and recurrence in patients with cancer.
Design Systematic review of published and
unpublished prospective observational studies.
Main outcome measures Survival from or recurrence
of cancer.
Results 26 studies investigated the association
between psychological coping styles and survival from
cancer, and 11 studies investigated recurrence. Most
of the studies that investigated fighting spirit (10
studies) or helplessness/hopelessness (12 studies)
found no significant associations with survival or
recurrence. The evidence that other coping styles play
an important part was also weak. Positive findings
tended to be confined to small or methodologically
flawed studies; lack of adjustment for potential
confounding variables was common. Positive
conclusions seemed to be more commonly reported
by smaller studies, indicating potential publication
bias.
Conclusion There is little consistent evidence that
psychological coping styles play an important part in
survival from or recurrence of cancer. People with
cancer should not feel pressured into adopting
particular coping styles to improve survival or reduce
the risk of recurrence.
Introduction
It is a popular belief that psychological factors can
influence survival from cancer, particularly breast
cancer.1 Current research interest in this subject stems
from 1979 when a small UK study found that a
psychological coping style characterised by a “fighting
spirit” was associated with longer survival from breast
cancer. A more negative style of coping characterised
as “helplessness/hopelessness” has also been reported
to predict a poorer outcome, though not all studies
have found such an association.2–6 It is important to
know whether these psychological factors do have an
influence on survival because psychological interven›
tions have been developed to enhance the use of
certain coping styles to prolong survival, and there is
strong lay and professional support for such therapies.7
Such as association is biologically plausible, and
several possible mechanisms have been proposed—for
example, through immunological and neuroendocrine
mechanisms.2 8 However there are conflicting views
regarding the importance of coping styles in the
progression of cancer, ranging from the view that they
have an important influence to the view that the theory
is characterised by myth and anecdote.9 10
We carried out a comprehensive systematic review
to assess the strength of the evidence for an association
between psychological coping and cancer outcome.
Methods
Search strategy—Following systematic review guide›
lines11 12 we searched several databases for published and
unpublished studies (in any language) on the association
between progression of cancer, recurrence or survival,
and psychological coping: Medline 1966›June 2002,
PsycINFO 1887›June 2002, ASSIA 1987›June 2002,
Embase 1980›June 2002, Cancerlit 1966–June 2002,
Dissertation Abstracts 1975›June 2002, the NLM
gateway (accessed 21 June 2002), and CINAHL
1982›June 2002. We searched bibliographies and
reviews and contacted key individuals and authors for
additional unpublished information when necessary.
Inclusion and exclusion criteria—We included pro›
spective cohort studies that included mortality,
survival, or recurrence as outcomes. We excluded stud›
ies of the association between coping and immune
responses or other biochemical markers, if this was the
only outcome reported, and studies of personality
types (for example, “type C” personality).
Data extraction and validity assessment—When the
results of both multivariate analyses and univariate
analyses were presented we extracted data from the
multivariate analysis and noted the variables used in
the adjustment (table 1 and 2). When necessary we
contacted authors for unpublished data; one author
supplied the requested information. Data were
extracted by one reviewer and checked by a second.
The studies were assessed independently by two
reviewers against three methodological criteria:
whether the sample represented an inception cohort,
the degree of adjustment for potential confounders,
and whether the assessment of coping was carried out
early in the disease process. The results were
summarised narratively.
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Results
We found 26 studies that investigated the association
between psychological coping and survival and 11
studies that investigated recurrence (figure). Some
studies were reported in more than one paper—for
example, results pertaining to different follow up peri›
ods. The most common diagnosis of patients in these
studies was breast cancer, though we also found studies
that investigated leukaemia, melanoma, and lung and
gastrointestinal cancers, with follow up periods
ranging from several months to 15 years (tables 1, 2,
and 3).
Assessment of validity
Thirteen studies met all three methodological criteria.
Table 3 shows methodological details of each study.
Table 1 shows studies of survival, and table 2 shows
studies of recurrence. About a third of all studies did
not adjust for potential confounding variables. Most of
the studies were small; the overall median sample size
was 125, and only four studies recruited more than 200
patients. There was no association between study qual›
ity (scored 1 to 3, see tables 1 and 2) and study outcome
(presence versus absence of significant findings; ÷2 test
for trend; P=0.5). Where studies are referred to as
“small” this is defined as “smaller than the median
study size.”
Findings
Fighting spirit—Ten studies investigated the impact of
“fighting spirit” on survival.2 3 5–7 13–20 Positive findings
that linked use of this coping style to longer survival
were confined to two small studies (table 1).2–5 20 Four
small studies examined the association with recurrence
of cancer. Three studies reported that fighting spirit
was associated with a reduced risk.2–4 6 15 This finding
was not confirmed by the fourth, larger study (n=578).7
Helplessness/hopelessness—Twelve studies examined
hopelessness/helplessness as a predictor of reduced
survival in cancer patients.2–4 6 7 13–19 21–25 Only two small
studies reported that more frequent such feelings
adversely affected survival.2 23 Five studies presented
data on recurrence of cancer, but the findings were
inconsistent.6 7 15 21 22 26 In one study, few data were pre›
sented15 and in another the outcome variable was a
composite variable based on a 13 point indicator of
clinical status.26 The two other studies that reported
associations with recurrence were small or limited by
methodological problems, or both. In particular, there
was limited control of confounding.2 21 22 The recent
large UK study (n=578), while of higher quality,
reported mixed findings: helplessness/hopelessness
predicted recurrence when those with high and low
scores were compared but not when it was the
predominant coping style.7
Denial or avoidance—Denial or avoidance were
assessed in 15 studies of survival; 10 of these
investigated avoidance1 7 8 13 14 17–19 27–29 and five investi›
gated denial.2–4 6 15 30 31 These studies did not report any
significant independent associations between the use of
an avoidant style of coping and survival. There was also
little evidence to suggest that denial was an important
predictor of survival1 7 13 27 28: two studies reported an
association between denial and survival but one
presented no supporting data.30 The other small study
found that the use of denial predicted death from breast
cancer at 10 and 15 years.2–4 Eight studies explored
the effects of denial or avoidance on recurrence of
cancer.2–4 6–8 15 20 32 33 Only one of these studies (a small
study carried out in patients with breast cancer)
reported that denial predicted recurrence.2–4 This
association was not reported in other larger studies.7 8
Stoic acceptance and fatalism—Nine studies explored
the impact of acceptance and fatalism,2 6 7 13–19 and
none of the four higher quality studies found that they
predicted survival.7 13 15 16 The evidence regarding
recurrence of cancer was similarly weak.2 6 7 15 The only
study that reported a significant association presented
no supporting data.15
Anxious coping/anxious preoccupation, depressive
coping—Ten studies investigated the impact of an anxious
or depressive coping style on survival.6 7 14–19 34–40 One
small study reported that higher anxious preoccupation
scores predicted shorter survival,13 and a study of 103
patients found that the use of depressive coping
predicted shorter survival.39 40 Three studies presented
relative risks associated with anxious preoccupation, all
of which were close to 1.0.7 13 18 19 One small study (n=35)
reported an association between depression and
survival, though this study had methodological draw›
backs with respect to patient recruitment and confound›
ing.38 None of these psychological factors was reported
to be significantly associated with recurrence of cancer.
Active or problem focused coping—Eight studies
explored the effects of active or problem focused cop›
ing on survival,1 8 27–29 34–37 39–41 one of which (n=103)
reported that the use of active coping was a predictor
of longer survival up to seven years.39 40 The largest
study (n=847) compared high, medium, and low users
of this coping style and found no association with sur›
vival after they controlled for clinical and socio›
demographic factors.1 Another study (n=133), which
investigated a coping style labelled “coping by control,”
reported no significant findings.41 Active or problem
focused coping was not associated with recurrence.
Emotional factors (including suppression of emotions
and emotion focused coping)—We identified six studies on
survival.1 7 23 29 30 34–37 One study (n=847) met the three
Potentially relevant studies of psychological states and
cancer identified and screened for retrieval (n=664)
Excluded from review (n=361)
• Not studies of cancer (n=126)
• Studies of stress, but not coping (20 case control studies of
    psychological stress and cancer risk; 20 other studies of stress)
• Other studies of cancer and life events (n=24)
• Reviews or commentary papers (n=120)
• Studies of personality types or psychological or social factors, and
    cancer risk or outcome (n=51)
Excluded: not primary studies of psychological
states and cancer in humans (n=269)
Papers retrieved for further evaluation (n=395)
Papers included with usable information (n=37)
Flowchart for main search. Search terms included: (cancer$ or
neoplasm$), expanded in Medline and other databases where
possible and denial or coping or attitude or fighting spirit or
avoidance or hope$ and (prognos$ or relapse or recurrence or
survival or progression)
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quality criteria and reported a positive association between expressing emotions (categorised as high,
Table 1 Prospective studies of survival from cancer and coping style* (posted as supplied by authors)
Sample size (%
women); mean age
at entry (years)
Coping style(s)
(scale used) Site of cancer
Length of
follow up (No
of deaths)
Adjustment for
confounders/
examination of
baseline variables† Results
Summary
of
results‡
Summary of
key
methodological
aspects of
study§
AchtØ (1979)30
Finland
126 (sex, age not
stated)
Denial, repression Not stated.
Malignancies of
digestive system or
urinary tract
excluded
Up to 3 years
(35)
None Poorer survival
associated with denial
and isolation, regression
and aggression; no data
presented
+ 1, 3
Andrykowski
(1994)13
USA
42 (38%); 34 years Fighting spirit,
hopelessness/
helplessness, anxious
preoccupation, fatalism
and avoidance (MAC48)
Chronic or acute
leukaemia, patients
undergoing bone
marrow transplant
Median survival
2.2 months
(27)
Quality of graft match,
diagnosis, age, time
from diagnosis to
transplant, stage, sex,
education
MAC anxious
preoccupation score
associated with poorer
survival (adjusted Cox
RR=1.2, 95% CI 1.04 to
1.3). Univariate HR for
other MAC scores:
fighting spirit 1.01 (0.95
to 1.1); helplessness/
hopelessness 0.92 (0.8 to
1.1); fatalism 0.99 (0.9 to
1.1)
− 1,2,3
Brown (2000)8
Australia
426 (39%); 53 years Active, distractive, and
avoidant coping;
adjustment to cancer
Early stage
melanoma
2 years (60) Clinical, demographic,
and psychological
factors
Higher avoidant coping
scores did not
independently predict
survival: HR=1.02 (1.00
to 1.05, P=0.08). Other
coping styles: not stated
− 1,2,3
Buddeberg
(1990, 1991,
1996,
1997)34›37
Switzerland
/Germany
107 (100%); 53
years
Depressive coping,
distrust and pessimism,
“regressive tendency”,
self encouragement,
distraction, self
revalorisation, control of
feelings and withdrawal,
problem solving (Zurich
coping questionnaire56 57)
Patients with breast
cancer without
metastases who had
undergone surgery 6
months earlier
3 years; 5›6
years; and 10
years (31)
3 years: none
5›6 and 10 years:
tumour size, node
status, radiotherapy,
chemotherapy, age
3 years: correlations
between coping and
death or metastases, self
rated coping (r=−0.04,
NS); depressive coping
(r=−0.01, NS); self
encouragement/
distraction (r=−0.05, NS);
problem tackling
(r=−0.11, NS)
5›6 and 10 years: coping
styles not related to
outcome
− 1, 3
(at 3 years)
1,2,3
(at 5›6, 10
years)
Butow (1999)27
Australia
125 (38%); 55 years Active, distractive, and
avoidant coping
Metastatic melanoma 2 years (deaths
not stated)
Range of demographic,
treatment, and clinical
variables considered
for inclusion in MVA
Coping scores did not
independently predict
survival. Univariate HR:
active coping 0.99 (0.96
to 1.03); distractive
coping 1.01 (1.03 to 1.2);
avoidant coping 0.98 (0.9
to 1.1); minimisation
predicted survival 0.93
(0.87 to 0.99)
− 1,2,3
Butow (2000)28
Australia
99 (100%); 57 years Active, distractive and
avoidant coping;
adjustment to cancer
(stigma/isolation,
minimisation, anger)
Metastatic breast
cancer
2 years (62) Age, sex, marital
status, time since
diagnosis, tumour site
and thickness,
ulceration, mitoses,
treatment, tumour site
Patients who minimised
impact of cancer on
social, work, and family
lives survived longer (HR
0.93 (0.88 to 0.98);
coping factors not
significant
− 1,2,3
Cassileth et al.
(1985, 1988)
22
USA
Group I:
unresectable
cancers; n=204
(37%); 60 years
Group II: n=155
(80%); 52 years
Hopelessness/
helplessness, amount of
adjustment required to
cope
Group I: pancreatic,
gastric, lung,
colorectal cancer, or
glioma
Group II: melanoma
or breast cancer
1985: group I
median survival
7 months;
group II
median 12
months to
recurrence
1988: follow up
at 3›8 years
(191 deaths)
1985: no adjustment;
no baseline clinical
differences
1988: diagnosis,
disease extent,
performance status,
marital status, age
group
1985: no association of
coping scores with
survival time (Mantel
Cox=1.3, P>010)
Hopelessness/
helplessness: 4.2 (group
1), 3.9 (group II) 1988:
(group I—high
adjustment associated
with risk of death:
RR=1.6 (1.1 to 2.3).
Hopelessness not
significant; no data
− 1,3 (1985)
1,2,3 (1988)
Cody (1994)14
UK
209 (29%); 64 years
(median)
Fighting spirit ,
helplessness, anxiety,
fatalism, avoidance48
Patients with new
diagnosis of
inoperable lung
cancer
8 weeks
(deaths not
stated)
Multivariate analysis
carried out; variables
not stated
No adjusted association
between denial, stoic
acceptance, helplessness,
hopelessness, fighting
spirit scores, and
survival. No other data
− 1,2
Dean and
Surtees
(1989)15 UK
125 (100%); 49
years
Stoic acceptance, fighting
spirit, denial,
hopelessness/
helplessness, anxious/
depressed51
Primary breast
cancer
6›8 years (22) Age, social class,
marital status,
menopausal status,
employment, tumour
size, node status
Patients employing denial
survived longer; P<0.1;
no other data
− 1,2,3
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Table 1 Prospective studies of survival from cancer and coping style* (posted as supplied by authors) contd
Sample size (%
women); mean age
at entry (years)
Coping style(s)
(scale used) Site of cancer
Length of
follow up (No
of deaths)
Adjustment for
confounders/
examination of
baseline variables† Results
Summary
of
results‡
Summary of
key
methodological
aspects of
study§
De Boer
(1998)49
Netherlands
133 (16%); 63 years
(median)
Uncertainty regarding
how to cope with illness
or emotions50
Head, neck
Stage I: 48%
Stage II: 13%
Stage III: 23%
Stage IV: 21%
6 years (57) Prior radiotherapy, T
and N classification,
age, education, marital
status, smoking,
drinking
High uncertainty scores
predicted shorter survival.
Uncertainty regarding
coping with practical
aspects of illness
(adjusted RR=1.11, 1.04
to 1.2); uncertainty
regarding coping with
emotions (0.93, 0.85 to
1.01)
+ 2,3
Derogatis
(1979)38
USA
35 (100%); 55 years Anxiety, depression,
hostility, guilt,
psychoticism,
psychological symptom
severity (defined by
authors as coping styles)
Metastatic breast
cancer
Long term
survivors
(mean=23
months) v
short term
survivors
(mean=9
months) (13)
None. No baseline
differences in age,
disease›free interval, %
premenopausal,
metastases, Karnofsky
score, response to
therapy
Survivors v
non›survivors: hostility
(t=2.4, P<0.01),
psychoticism (t=2.7,
P<0.01), depression
(t=2.3, P<0.05), guilt
(t=2.6, P<0.05), negative
affect (t=2.7, P<0.01),
affect balance (t=2.1,
P<0.05)
+ 3
Faller (1997;
1999; and
unpublished
data)39 40
Germany
103 (17%); 59 years Depressive coping, active
coping, hope35 57
Lung cancer
Stage 1: 2%,
Stage II: 7%
Stage IIIa/IIIb: 49%
Stage IV: 42%
(i) 3›5 years
(ii) 5›7 years
(92)
(i) Karnofsky status,
treatment, stage
(ii) Histology, stage,
Karnofsky status,
treatment
Use of active coping
predicted longer survival
(3›5 years RR=1.91, 1.17
to 3.12; also 5›7 years
RR=0.68, 0.50 to 0.94).
Use of depressive coping
predicted shorter survival
(RR=1.88, 1.29 to 2.73)
+ 1,2,3
Giraldi (1997)16
Italy
95 (100%); 51 years Fighting spirit,
hopelessness, anxious
preoccupation, fatalism48
Breast cancer
T1: 36%
T2: 41%
6 years
(15)
Nodal status, histology,
tumour stage,
oestrogen receptor
status
High v low fighting spirit
score: RR=1.08, 0.94 to
1.23
High v low hopelessness
score: unadjusted
RR=0.9, 0.72 to 1.12; no
other data
− 1,2,3
Greer (1979),2
Pettingale
(1984),3
Pettingale
(1985),4
Greer
(1990)5 UK
69 (100%); aged
<70 years
Denial, fighting spirit,
stoic acceptance,
helplessness/
hopelessness
Breast cancer with
no metastases
5, 10, 15 years
(34, 36, 47)
5 years: none
10 years: age,
menopausal status,
stage, operation,
radiotherapy, histology
15 years: age,
menopausal status,
stage, operation,
radiotherapy, histology
5 years: use of stoic
acceptance or
helplessness/
hopelessness and risk of
death RR=4.4, 1.1 to
17.0)
10 years: use of denial or
fighting spirit predicted
death, and death from
breast cancer (P=0.003)
15 years: denial, fighting
spirit predicted death
(z=2.83, P=0.006), death
from cancer (z=3.6,
P<0.001)
+
+
+
1,3 (at 5 years)
1,2,3 (at 10
years)
1,2,3 (at 10
years)
Hislop (1987)41
Canada
133 (100%); <55
years at diagnosis
Coping by change, by
control, by stress
Primary ductal
breast cancer
4 years
(26)
Age, stage, pathological
nodal status,
histological grade, ER
status
Coping by change (more
v less often): Cox
adjusted RR=0.59, no CI,
P=0.3 Coping by control:
RR=0.59 Coping by
stress: RR=1.4, P=0.6
− 1,2,3
Molassiotis
(1997)23 UK
31 (29%); 34 years Emotion focused coping,
humour, withdrawal,
acceptance, hopefulness
(Jalowiec coping scale52)
Patients with bone
marrow transplant:
haematological
malignancies
1›2 years (20) Age, sex, marital
status, ethnicity,
diagnosis, quality of
raft match, stage,
previous treatment
Frequent use of hope
(Cox adjusted RR=0.11,
0.02 to 0.52) and less
frequent use of
acceptance (1.4, 1.3 to
13.4) predicted long term
survival
+ 1,2,3
Morris (1992)6
UK
107 (100%)
61 (26%)
Denial, fighting spirit,
anxious preoccupation,
stoic acceptance,
helpless/hopelessness
Breast cancer
(n=107)
Lymphoma (n=61)
Up to 5 years
(20)
Age, sex, stage,
tumour grade,
non›Hodgkin’s
lymphoma, type of
operation, tumour size,
positive nodal status
Breast cancer: no coping
style predicted survival
Lymphoma: anxious
preoccupation/stoicism/
helplessness›hopelessness
associated with survival.
All cases: association
found between
“prognostic index” and
primary coping style (÷2
for survival 5.49, P=0.02)
− (breast
cancer)
+
(lymphoma)
+ (all
cases)
1,2
Murphy
(1996)17 UK
56 (48%); 35 years Fighting spirit ,
helplessness, anxiety,
fatalism, avoidance48
Patients with bone
marrow transplant:
leukaemia: 68%
lymphoma: 25%
aplastic anaemia:
8%
Mean follow
up: 82 months
(18)
Unadjusted No difference in mean
survival time between
patients with fighting
spirit as predominant
coping style and others
(P=0.79; no other data).
− 1,3
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medium, or low) and longer survival (hazard ratio 0.6,
95% confidence interval 0.4 to 0.9).1 Another large
good quality study examined the impact of emotional
suppression on outcome but found no significant asso›
ciations with either overall or event›free survival.7
Publication bias
We could not carry out standard methods of assessing
publication bias such as funnel plots because there was
great heterogeneity among the studies and there were
only a small number of studies in each category of
coping style. Studies that reported “positive” findings
were smaller than those that reported non›significant
findings (mean sample size 89 v 198, P=0.02, two
tailed), which is indicative of publication bias.
Table 1 Prospective studies of survival from cancer and coping style* (posted as supplied by authors) contd
Sample size (%
women); mean age
at entry (years)
Coping style(s)
(scale used) Site of cancer
Length of
follow up (No
of deaths)
Adjustment for
confounders/
examination of
baseline variables† Results
Summary
of
results‡
Summary of
key
methodological
aspects of
study§
Nordin and
Glimelius
(1997,
1998)18 19
Sweden
139 (51%); 67 years Fighting spirit,
helplessness, anxious
preoccupation, anxiety,
fatalism, avoidance48
Gastrointestinal
cancers (colon:
27%, rectum: 23%,
gastric: 24%,
pancreatic: 16%,
biliary: 12%)
< 12 months
(56)
No adjustment; cured
and non›cured patients
did not differ in age,
time since diagnosis,
or sex
At 6 months: fighting
spirit as predominant
style RR=0.86, 0.61 to
1.19); helplessness/
hopelessness 1.19, 0.84
to 1.69); anxious
preoccupation 1.03 (0.7
to 1.5); fatalism 0.88,
0.56 to 1.39)
− 1,3
Reynolds
(2000)1 USA
847 (100%) Expressing/suppressing
emotions, wishful
thinking, problem solving,
positive reappraisal,
avoidance, escapism, size
of “coping repertoire”
Breast cancer Up to 9 years
after diagnosis
(218)
Age, study location,
race, stage,
comorbidity, weight,
progesterone and
oestrogen receptor
status
Expressing emotions
increased survival
(HR=0.6, 0.4 to 0.9);
suppression reduced
survival (1.4, 1.1 to 1.9);
wishful thinking 0.9, 0.7
to 1.3); problem solving
0.8, 0.6 to 1.2); positive
reappraisal 1.1, 0.7 to
1.6); avoidance 0.8, 0.6
to 1.1); escapism 1.1, 0.7
to 1.5). HRs refer to high
v low use of coping style
+/− 1,2,3
Richardson
(1990)29 USA
139 (35%); from
<20 to >80 years
Behavioural and cognitive
coping, including
avoidance, information
seeking, problem solving,
affective regulation53
Haematological
malignancies (n=92)
Rectal cancer (n=47)
4 years 10
months (rectal
cancer); <5
years
(haematological
cancers) (64)
Unadjusted No significant association
with outcome in either
group. RR for high v low
avoidance: (i) 1.08, 0.32
to 2.44; (ii) 0.71, 0.32 to
1.62)
− 1,3
Ringdal
(1995),25
(1996)24 USA
253 (45%); 57 years Hopelessness (Beck
hopelessness scale54)
Breast: (25%)
Gastrointestinal:
(11%)
Prostate: 12%
Lung: 11%)
Lymphomas: 13%
Mean survival
time 7 months
(131)
Age, sex, treatment
intention, physical
functioning, cancer
type, treatment
modality, relapse
Cox unadjusted RR for
hopelessness 1.11, 1.06
to 1.17). Association
disappeared in
multivariate analysis
− 2,3
Schulz (1996)55
USA
268 (51%); >30
years
Pessimism, optimism Recurrent/
metastasised breast:
23%
Lung: 20%
Head/neck: 13%
Gynaecological: 9%
Other cancers
8 months (70) Type of cancer,
symptoms at baseline
No direct or indirect
effects of optimism score
on mortality. Pessimism
score did not
independently predict
mortality (adjusted
RR=1.1, 0.97 to 1.2)
− 2,3
Silberfarb
(1991)31 USA
290 (46%);
13% <49 years 27%
<59 years 33% <69
years
Denial of illness Previously untreated
patients with
multiple myeloma
2 years (deaths
not stated)
Age, tumour cell load,
creatinine, “usual
prognostic factors”
No association of denial
with survival; no other
data
− 1,3
Tschuschke
(2001)20
Germany
52 (31%); 36 years Passive
reception/resignation,
distraction, cognitive
structuring, social
contact, compliance,
fighting spirit
Patients with acute
(n=33) and chronic
(n=19) myeloid
leukaemia
undergoing bone
marrow
transplantation
Mean survival
time 2.6 years
(21)
Stage, leukaemia type,
age, sex. Distraction,
fighting spirit
subgroups similar in
education, marital
status, social support,
GvHD prophylaxis
Distraction (Wald=7.27,
P=0.007), fighting spirit
(6.31, P<0.012)
associated with survival.
RRs estimated from
survival curve: high v low
distraction 0.61; high v
low fighting spirit 0.65
+ 2,3
Watson (1999)7
UK
578 (100%); 55
years
Fighting spirit,
helplessness/
hopelessness, anxious
preoccupation, fatalism,
avoidance (MAC scale48),
emotional suppression
Stage I and II breast
cancer
5 years (133) Histopathological
grade, number of +ve
lymph nodes, tumour
size, type of operation,
chemotherapy v
endocrine therapy,
oestrogen receptor
status
No effect of predominant
coping style, or emotional
suppression. Fighting
spirit HR=0.86, 0.42 to
1.76; H/H 0.95, 0.46 to
1.98; anxiety
preoccupation 1.04, 0.5
to 2.2; fatalism 1.02, 0.49
to 2.15; avoidance 1.53,
0.72 to 3.28)
Mainly
negative
1,2,3
RR=relative risk; HR=hazard ratio; NS=non›significant.
*Some studies investigated both survival and recurrence and therefore appear in table 2 also.
†In addition to psychosocial variables.
‡+=mainly significant associations found; 0=no significant associations; +/−=mixed positive and negative findings.
§1=patients recruited near to diagnosis; 2=adjustment for at least one confounder; 3=early assessment of coping style.
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Table 2 Prospective studies of recurrence of cancer and coping style* (posted as supplied by authors)
Sample size (%
women); mean age
at entry (years)
Coping style(s)
(scale used)
Site of cancer and
stage
Length of
follow up
Adjustment for
confounders/
examination of
baseline variables† Results
Summary
of
results‡
Summary of key
methodological
aspects of study§
Brown (2000)8
Australia
426 (39%); 53 years Active, distractive and
avoidant coping;
adjustment to cancer
(stigma/isolation,
minimisation, anger)
Early stage
melanoma
2 years Clinical, demographic,
and psychological
factors
Avoidant coping scores
and recurrence:
HR=1.02, 95% CI 1.00 to
1.04, P=0.03. Other
coping styles not stated
+ 1,2,3
Cassileth
(1985,
1988)21 22
USA
Group I:
unresectable
cancers; n=204
(37%); 60 years
Group II: stage I/II
melanoma, stage II
breast cancer;
n=155 (80%); 52
years
Hopelessness/
helplessness,38 amount
of adjustment required
to cope with diagnosis
Group I:
unresectable
pancreatic, gastric,
non›small cell lung
cancer, colorectal
cancer, or grade 3
or 4 glioma
Group II: melanoma
or breast cancer
1985: group I:
median
survival 7
months);
group II: time
to recurrence
12 months.
1988: 3›8
years
1985: unadjusted.
1988: diagnosis,
disease extent,
performance status,
marital status, age
group
1985: recurrence, no
unadjusted association of
psychosocial categories
with recurrence (Mantel
Cox statistic=4.4,
P>0.10). 1988: time to
recurrence (group II):
“intermediate” level of
hopelessness: Cox
RR=0.52, 0.28 to 0.96,
P=0.03 (adjusted for
psychosocial variables
only)
−
+
1,3 (1985)
1,2,3 (1988)
Dean and
Surtees
(1989)15
UK
125 (100%); 49
years
Stoic acceptance,
fighting spirit, denial,
hopelessness/
helplessness,
anxious/depressed51
Primary breast
cancer
6›8 years Age, social class,
marital status,
menopausal status,
employment, tumour
size, node status
Patients who employed
hopelessness/
helplessness and stoic
acceptance were more
likely to be
recurrence›free at follow
up; use of denial at 3
months associated with
being recurrence free; no
other data.
+ 1,2,3
De Boer
(1998)49
Netherlands
133 (16%); 63 years
(median)
Uncertainty regarding
how to cope with
illness, or emotions50
Head, neck cancer.
Patients received
radiotherapy,
laryngectomy, or
other surgery. Stage
I: 48%, II: 13%, III:
23%, IV: 21%
6 years Previous radiotherapy,
T and N classification,
age, education, marital
status, smoking,
drinking
Higher uncertainty
regarding coping with
practical aspects of
illness (adjusted RR for
uncertainty score=1.03,
0.96 to 1.11); uncertainty
regarding coping with
emotions (0.98, 0.90 to
1.07)
+ 2,3
Epping›Jordan
(1994)32
USA
66 (72%); 41 years Avoidance (impact of
events scale)58
Breast (38%),
gynaecological
(19%),
haematological
(14%), brain (9%),
malignant melanoma
(5%)
1 year Age, severity,
physician’s prognosis,
number of treatments,
distress
High avoidance score
predicted poorer disease
status (composite
variable including
recurrence) at 1 year
(adjusted OR=0.81,
P=0.19)
+ 1,2,3
Greer (1979)2
Pettingale
(1984),3
Pettingale
(1985),4
Greer
(1990)5 UK
69 (100%); <70
years
Denial, fighting spirit,
stoic acceptance,
helplessness/
hopelessness
Breast cancer with
no metastases,
treated by
mastectomy; 25 also
received
radiotherapy
5, 10, and 15
years
5 years: none. 10
years: age,
menopausal status,
stage, operation,
radiotherapy, histology.
15 years: age,
menopausal status,
stage, operation,
radiotherapy, histology
5 years: recurrence or
death. Use of denial
RR=1.57, 0.94 to 2.62,
fighting spirit 1.88, 1.19
to 2.96, and either
coping strategy v
acceptance or
helplessness/
hopelessness 3.1, 1.3 to
7.4. 10, 15 years: use of
denial or fighting spirit
predicted recurrence
+ 1,3 (at 5 years)
1,2,3 (at 10 years)
1,2,3 (at 10 years)
Hislop (1987)41
Canada
133 (100%); <55
years at diagnosis
Coping by change, by
control, by stress
Primary ductal
breast cancer
4 years Age, stage,
pathological nodal
status, histological
grade, ER status
No effect of coping
variables (high v low use
of coping style) on
recurrence. Coping by
change Cox adjusted
RR=0.6, no CI, P=0.12;
coping by control 0.95,
P=0.9; coping by stress
1.1, P=0.8
− 1,2,3
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Discussion
It is commonly believed that a person’s mental attitude
in response to a diagnosis of cancer affects his or her
chances of survival, and the psychological coping
factors that are most well known in this respect are
fighting spirit and helplessness/hopelessness.42 We
found little convincing evidence that either of these
factors play a clinically important part in survival from
or recurrence of cancer; the significant findings that do
exist are confined to a few small studies. Good evidence
is also lacking to support the view that “acceptance,”
“fatalism,” or “denial” have an important influence on
outcome.
Our review has several possible limitations. Firstly,
the validity assessment focused on only three method›
ological criteria and other criteria are known to be
important, such as the adequacy of baseline infor›
mation.43 However, when we piloted the validity assess›
ment checklist these criteria did not seem to
differentiate adequately between the studies. We could
have adopted a more stringent set of criteria, but this
would be unlikely to alter the (already negative)
conclusions of the review.
The review may also be subject to publication bias
because the studies reporting “positive” findings
tended to be smaller. We tried to identify unpublished
studies, including theses and conference papers, but
small studies with negative findings are less likely to be
published in any form and thus may be more difficult
to locate.44 Among the studies that we did identify, rela›
tively few had adequately adjusted for important
predictors of disease›free and overall survival, such as
age and histological grade,45 and this is a possible
explanation for some of the positive findings.
Overall we found little evidence that coping styles
play an important part in survival from cancer. This is
an important finding because there is often pressure
on patients with cancer to engage in “positive
thinking,” and this may add to their psychological
burden.46 47 It has been suggested that clinicians need
to detect coping styles such as helplessness or
hopelessness and treat them vigorously.7 Our findings
show that such interventions may be inappropriate, at
least when they are used with the aim of increasing
survival or reducing the risk of recurrence.
Table 2 Prospective studies of recurrence of cancer and coping style* (posted as supplied by authors) contd
Sample size (%
women); mean age
at entry (years)
Coping style(s)
(scale used)
Site of cancer and
stage
Length of
follow up
Adjustment for
confounders/
examination of
baseline variables† Results
Summary
of
results‡
Summary of key
methodological
aspects of study§
Jensen
(1987)26
USA
Group I: women
with recurrence or
metastasis (n=27;
50 years); group II:
women with
minimum 2 years in
remission (n=25; 49
years); group III:
non›cancer controls
(n=34, age not
given)
Defensiveness,
helplessness/
hopelessness, negative
affect, chronic stress,
and daydreaming
(Millon behavioural
health inventory,
MBHI26)
Breast cancer Average follow
up 624 days
Groups similar in
stage, age, weight, age
at menarche, and first
pregnancy, parity, SES,
family history, disease
course, positive nodes.
Adjusted for age,
stage, cancer duration,
packed cell volume,
alkaline phosphatase
Defensiveness (presence
v absence) F=4.4,
P=0.04;
helplessness/
hopelessness score
F=9.6, P=0.0006;
negative affect score
F=2.2, P=0.004; chronic
stress F=5.7, P=0.02;
and daydreaming score
F=10.4, P=0.003, were
independently associated
with clinical and vital
status (composite
variable based on final
disease status)
+ 1,2
Morris (1992)6
UK
107 (100%)
61 (26%)
Denial, fighting spirit,
anxious preoccupation,
stoic acceptance,
helpless/hopelessness
Breast cancer
(n=107); lymphoma
(n=61)
Up to 5 years Age, sex, stage,
tumour grade,
non›Hodgkin’s
lymphoma, type of
operation, tumour size,
nodal status
Breast cancer,
lymphoma: no coping
style predicted
recurrence. All:
association between
prognostic index and
style of coping (÷2 for
recurrence=6.1, P=0.02)
− 1,2
Rogentine
(1979)33
USA
Study 1: 67 (25%);
16›67 years
Adjustment needed to
cope with cancer
(“denial”)59
Malignant
melanoma. All
patients disease free
at point of testing
Recurrence at
1 year
Stage, positive/
enlarged nodes,
histology, Clark level,
location of primary,
age, sex, time from
symptoms to diagnosis
Amount of adjustment
required lower in patients
with relapse (mean
score=53 v 80, P<0.001).
Adjustment score did not
correlate with number of
positive nodes
+ 2,3
Watson
(1999)7
UK
578 (100%); 55
years
Fighting spirit,
helplessness/
hopelessness, anxious
preoccupation,
fatalism, avoidance,48
emotional suppression
Stage I and II breast
cancer
5 years Histopathological
grade, positive lymph
nodes, tumour size,
operation,
chemotherapy v
endocrine therapy, ER
status
No effect of predominant
coping style or emotional
suppression on
event›free survival. Only
helplessness/
hopelessness significant
(high v low scorers)
(RR=1.55, 1.07 to 2.25)
but not when it was
predominant coping
response (1.15, 0.60 to
2.22)
+/− 1,2,3
RR=relative risk; HR=hazard ratio; OR=odds ratio.
*Some studies investigated both recurrence and survival and therefore appear in table 1 also.
†In addition to psychosocial variables.
‡+=mainly significant associations found; 0=no significant associations; +/−=mixed positive and negative findings.
§1=clearly defined group of patients recruited near to diagnosis, 2=adjustment for at least one confounder, 3=early assessment of coping style
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Conclusion
Good evidence in this subject is still scarce as there
have been few large methodologically sound studies.
Although the relation is biologically plausible, there is
at present little scientific basis for the popular lay and
clinical belief that psychological coping styles have an
important influence on overall or event›free survival in
patients with cancer.
We are grateful to those who supplied additional data, Herman
Faller, Allan House, and Sue Lockwood who commented on
earlier versions of the paper, and Susan Kennedy for help with
redrafting.
We carried out a supplementary search in June 2002 to update
the review while it was undergoing peer review: Medline 117
additional hits; PsycLit 88 additional hits; Assia 23 additional
hits; Embase 113 additional hits; Cancerlit 115 additional hits;
Dissertation Abstracts 88 additional hits; Healthstar no longer
existed but is now part of NLM gateway and this was searched
instead, 220 additional hits from Oct 2001›June 2002; CINAHL
Table 3 Details of studies of survival and recurrence
Sample size Coping style(s) (scale used) Site of cancer
Outcomes included in study, length of follow
up (No of deaths)
Reynolds1 847 Expressing/suppressing emotions, wishful
thinking, problem solving, positive
reappraisal, avoidance, escapism, “coping
repertoire”
Breast Survival: up to 9 years (218 deaths)
Greer,2 5 Pettingdale,3 4 69 Denial, fighting spirit, stoic acceptance,
helplessness/hopelessness
Breast Survival: 5, 10, and 15 years (34, 36, 47
deaths respectively); recurrence
Morris6 168 Denial, fighting spirit, anxious preoccupation,
stoic acceptance, helplessness/hopelessness
Breast, lymphoma Survival: up to 5 years (20 deaths);
recurrence
Watson7 578 Fighting spirit, helplessness/hopelessness,
anxious preoccupation, fatalism, avoidance,48
emotional suppression
Breast Survival: 5 years (133 deaths); recurrence
Brown8 426 Active, distractive, and avoidant coping;
adjustment to cancer
Early stage melanoma Survival: 2 years (60 deaths); recurrence
Andrykowski13 42 Fighting spirit, hopelessness/helplessness,
anxious preoccupation, fatalism, avoidance48
Leukaemia Survival: median=2.2 months (27 deaths)
Cody14 209 Fighting spirit, helplessness, anxiety, fatalism,
avoidance48
Lung Survival: 8 weeks (deaths not stated)
Dean15 125 Stoic acceptance, fighting spirit, denial,
hopelessness/helplessness, anxious/
depressed51
Breast Survival: 6›8 years (22 deaths); recurrence
Giraldi16 95 Fighting spirit, hopelessness, anxious
preoccupation, fatalism48
Breast Survival: 6 years (15 deaths)
Murphy17 56 Fighting spirit, helplessness, anxiety, fatalism,
avoidance48
Leukaemia, lymphoma, aplastic anaemia Survival: mean=82 months (18 deaths)
Nordin18 19 139 Fighting spirit, helplessness, anxious
preoccupation, anxiety, fatalism, avoidance
(MAC scale)48
Colorectal, gastric, pancreatic, and biliary
cancers
Survival: <12 months (56 deaths)
Tschuschke20 52 Passive reception/resignation, distraction,
cognitive structuring, social contact,
compliance, fighting spirit
Leukaemia Survival: mean survival time=2.6 years (21
deaths)
Cassileth21 22 204 +155 Hopelessness/helplessness, amount of
adjustment required to cope with diagnosis
Pancreatic, gastric, lung, colorectal cancer,
glioma, melanoma, or breast
Survival:1985—group I median survival 7
months; group II median 12 months to
recurrence
1988—follow up at 3›8 years; recurrence
Molassiotis23 31 Emotion focused coping, humour,
withdrawal, acceptance, hopefulness52
Haematological malignancies Survival: 1›2 years (20 deaths)
Ringdal24 25 253 Hopelessness54 Breast, gastrointestinal, prostate, lung;
lymphoma
Survival: mean survival time=17 months
Jensen26 86 Defensiveness, helplessness/hopelessness,
negative affect, chronic stress, and
daydreaming
Breast Recurrence: average follow up=624 days (11
deaths)
Butow27 125 Active, distractive, avoidant coping Metastatic melanoma Survival: 2 years (deaths not stated)
Butow28 99 Active, distractive and avoidant coping;
adjustment to cancer (stigma/isolation,
minimisation, anger)
Metastatic breast Survival: 2 years (62 deaths)
Richardson29 139 Behavioural and cognitive coping, including
avoidance, information seeking, problem
solving, affective regulation53
Haematological malignancies, rectal Survival: <5 years (64 deaths)
AchtØ30 126 Denial, repression Not stated Survival: up to 3 years (35 deaths)
Silberfarb31 290 Denial of illness Multiple myeloma Survival: 2 years (deaths not stated)
Buddeberg34 35 36 37 107 Depressive coping, distrust and pessimism,
“regressive tendency,” self encouragement,
distraction, self revalorisation, control of
feelings and withdrawal, problem solving)56 57
Breast Survival: 3 years; 5›6 years; 10 years
Derogatis38 35 Anxiety, depression, hostility, guilt,
psychoticism, general psychological symptom
severity index (defined by author as study of
coping)
Breast Survival: long term survivors (mean=23
months) v short term survivors (mean=9
months) (13 deaths)
Faller39 40 103 Depressive coping, active coping, hope Lung Survival: up to 7 years
Hislop41 133 Coping by change, by control, by stress Breast Survival: 4 years (26 deaths); recurrence
De Boer49 133 Uncertainty regarding how to cope with
illness, or emotions50
Head, neck Survival: 6 years (57deaths); recurrence
Schulz55 268 Pessimism, optimism Breast, lung, head, neck, gynaecological,
other
Survival: 8 months
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60 additional hits from Aug 2001 to June 2002. None of these
abstracts was relevant to the review and none met the inclusion
criteria.
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included studies. All authors contributed to interpreting the evi›
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Funding: MP is funded by the Chief Scientist Office of the Scot›
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